A Phase 1, Open-label Study to Characterize Single and Repeat Dose Pharmacokinetics (Including Food Effect) of Tebipenem-pivoxil-hydrobromide and Its Major Metabolite (SPR1349) in Healthy Participants

The main purpose of the study is to characterize the systemic pharmacokinetic (PK) parameters (plasma, whole blood) of tebipenem (TBP) pharmacologically active moiety of tebipenem-pivoxil-hydrobromide (TBP-PI-HBr) and its urinary excretion at different dose levels in healthy participants. The study also aims to assess the plasma and urine PK parameters of SPR1349, a major metabolite of TBP.

开始日期2024-11-20

申办/合作机构

Spero Therapeutics, Inc.

[+1]

CTR20241033

/ CompletedN/A

替比培南匹伏酯细粒剂在健康受试者中随机、开放、两制剂、两序列、单次给药、两周期交叉设计空腹和餐后状态下生物等效性试验

主要目的：以石药集团中诺药业（石家庄）有限公司生产的替比培南匹伏酯细粒剂为受试制剂，以Meiji Seikaファルマ的替比培南匹伏酯细粒剂（商品名：ORAPENEM）为参比制剂，按生物等效性试验的相关规定，比较替比培南匹伏酯细粒剂在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：评价健康受试者单次空腹/餐后口服替比培南匹伏酯细粒剂受试制剂和参比制剂后的安全性。研究替比培南匹伏酯细粒剂在健康受试者血浆和尿液中可能的代谢产物，研究替比培南在尿液中的PK特征。

开始日期2024-04-17

申办/合作机构

石药集团中诺药业（石家庄）有限公司

NCT06059846

/ Completed临床3期

A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Multinational Study to Assess the Efficacy and Safety of Orally Administered Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenously Administered Imipenem-cilastatin in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

The primary purpose of this study is to assess the efficacy of oral TBP-PI-HBr as compared with intravenous (IV) imipenem-cilastatin with respect to the overall response (combined clinical cure plus microbiological eradication) at the Test-of-Cure (TOC) visit in hospitalized adult participants (≥18 years of age) with cUTI or AP.

开始日期2023-12-21

申办/合作机构

Spero Therapeutics, Inc.

[+1]

100 项与替比培南酯相关的临床结果

登录后查看更多信息

100 项与替比培南酯相关的转化医学

登录后查看更多信息

100 项与替比培南酯相关的专利（医药）

登录后查看更多信息

211

项与替比培南酯相关的文献（医药）

2025-06-01·JOURNAL OF INFECTION AND CHEMOTHERAPY

Antimicrobial activity of tebipenem to Escherichia coli isolates from outpatients with complicated urinary tract infections

Article

作者: Tanaka, Kaori ; Hayashi, Masahiro ; Yasuda, Mitsuru ; Ito, Masaya

Extended-spectrum β-lactamases (ESBL)-producing Escherichia coli have emerged as a global concern in urinary tract infections (UTIs). This study investigated the susceptibility of clinical isolates of E. coli from complicated UTIs (cUTIs) to tebipenem pivoxil (TBPM), an oral carbapenem developed in Japan. In 2019, 229 non-ESBL-producing and 61 ESBL-producing E. coli strains were collected from five major hospitals in the Gifu Prefecture. Susceptibility was assessed following the Clinical and Laboratory Standards Institute guidelines (M07 and M100), and TBPM was compared with other commonly used antibiotics. The MIC₅₀ and MIC₉₀ values of TBPM for non-ESBL and ESBL-producing E. coli were ≤0.03 μg/mL, with MIC ranges of ≤0.03-0.25 μg/mL and ≤0.03-0.06 μg/mL, respectively, indicating its strong antimicrobial activity. Notably, no strains demonstrated reduced susceptibility to TBPM. These results were comparable to those of intravenous carbapenems such as imipenem and meropenem. Additionally, these findings align with the national Japanese surveillance data, suggesting that the trends observed in this study may reflect broader patterns across Japan. In the United States, an ongoing study is evaluating TBPM hydrobromide for cUTIs, highlighting its potential as an effective oral carbapenem. TBPM may be a promising treatment option for cUTIs caused by ESBL-producing E. coli, offering an alternative to intravenous therapies and potentially reducing the need for hospitalization. However, careful use of TBPM in antimicrobial stewardship programs is crucial to prevent resistance and ensure its continued efficacy in outpatient settings.

2025-06-01·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Both carvedilol and cimetidine alleviate cisplatin-induced nephrotoxicity via downregulating OCT2

Article

作者: Jiao, Xiaoyan ; Wu, Huan ; Ning, Yichun ; Sun, Zhaoxing ; Ji, Ji ; Yu, Xiaofang ; Ding, Xiaoqiang ; Cheng, Xin ; Xu, Xiaoliang ; Lu, Min

BACKGROUND:

Cisplatin is a common chemotherapy agent for solid tumors but severe nephrotoxicity limits its application, with no effective pharmacological treatments. Organic cation transporter 2 (OCT2) is involved in cisplatin uptake in kidneys. This study aimed to find drugs with promising clinical applications that could prevent cisplatin-induced acute kidney injury (Cis-AKI) by inhibiting OCT2.

METHODS:

The mRNA level of OCT2 was examined in human induced pluripotent stem cells (iPSCs) from Cis-AKI patients and paired non-AKI patients. The association between OCT2 and Cis-AKI was investigated by HEK293FT cells and kidney organoids. We screened potential compounds exhibiting protective effects against Cis-AKI in US Food and Drug Administration-approved drugs through virtual screening and activity screening. Subsequently, we determined the effects of these compounds on OCT2 expression, cisplatin uptake, and apoptosis in cells, kidney organoids and mice. A549 and HeLa cells were adopted to observe the influence of drugs on the anti-tumor function of cisplatin.

RESULTS:

Compared to non-AKI patients, the OCT2 mRNA levels of iPSCs from Cis-AKI patients were elevated. OCT2 exhibits similar expression patterns in kidney organoids and human kidney tissues. Furthermore, the overexpression of OCT2 in kidney organoids and HEK293FT cells exacerbated the injury caused by cisplatin. Carvedilol and cimetidine were identified as potent OCT2 inhibitors by drug screening. Further analysis revealed that the pretreatment of carvedilol or cimetidine downregulated OCT2, reduced cisplatin uptake, and alleviated cisplatin-induced apoptosis, but the combination of the two drugs didn't further improve these outcomes. Additionally, carvedilol and cimetidine didn't compromise the cisplatin-induced cell death in A549 and HeLa cells.

CONCLUSION:

Our study confirmed that carvedilol and cimetidine exert protective effects against Cis-AKI by inhibiting OCT2, without altering the anti-tumor effects of cisplatin.

2025-05-07·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024)

Article

作者: Westblade, Lars F. ; Chamberland, Robin ; Sfeir, Maroun M. ; Srodon, Monica ; Mochon, A. Brian ; Fouad, Aliaa ; Asempa, Tomefa E. ; Martin, Isabella W. ; Taylor, Kimberly ; Wang, Yungchou ; Munson, Erik ; Bobenchik, April M. ; Huse, Holly K. ; Nicolau, David P. ; Clark, Andrew E.

ABSTRACT:

Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates ( n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.

131

项与替比培南酯相关的新闻（医药）

2025-05-29

·药明康德

超90%患者肿瘤缩小！潜在“best-in-class”小分子达3期主要终点；潜在首款！GSK小分子有望今年递交上市申请……

潜在首款！GSK小分子疗法关键3期试验达主要终点，今年递交上市申请GSK与Spero Therapeutics今日宣布，其所开发的抗生素tebipenem HBr在关键3期PIVOT-PO临床试验中取得积极结果。基于该疗法用于治疗复杂性尿路感染（cUTI，包括肾盂肾炎）患者的中期分析疗效数据，独立数据监查委员会（IDMC）建议提前终止试验。GSK预计将在2025年下半年将试验结果递交给美国FDA，作为上市申请的一部分。根据新闻稿，如果获得批准，tebipenem HBr将成为治疗cUTI的首个美国FDA批准的口服碳青霉烯类抗菌药物。此次试验结果包含入组的1690例患者的数据。分析显示，试验达到主要终点：在住院cUTI（包括肾盂肾炎）成人患者中，tebipenem HBr在治愈评估访视（test-of-cure visit）时的总缓解率（包括临床治愈和微生物清除的复合指标）不劣于静脉注射的亚胺培南-西司他丁。IDMC在审查过程中未发现该药物新的安全问题，最常见的不良事件为腹泻和头痛。Tebipenem HBr（原名SPR994）是Spero所开发的一种碳青霉烯类口服抗生素。该抗生素自2009年起以商品名Orapenem在日本用于治疗肺炎、中耳炎和鼻窦炎的儿科感染。碳青霉烯类是抗生素的一个重要子类，已观察到它们在治疗耐药革兰氏阴性细菌感染方面是安全有效的。GSK在2022年9月取得该疗法的独家许可，使其可在除日本和某些其他亚洲国家和地区以外的所有地区对tebipenem HBr进行商业化。首款！百时美施贵宝单抗皮下制剂获欧盟委员会批准百时美施贵宝（Bristol Myers Squibb）今日宣布，欧盟委员会（EC）已批准Opdivo（nivolumab，纳武利尤单抗）皮下注射剂（600 mg/瓶），用于多种成人实体瘤的治疗，包括单药治疗、静脉注射Opdivo联合Yervoy（伊匹单抗）治疗后的单药维持治疗，或与化疗或卡博替尼联合使用。根据新闻稿，Opdivo是在欧盟首个获批可皮下注射使用的PD-1抑制剂。这次欧盟委员会的批准主要基于CheckMate-67T的临床试验结果，显示Opdivo皮下注射剂（n=248）与静脉注射剂（n=247）在药代动力学（PK）和安全性方面的结果一致。分析显示，在既往接受不超过两种系统性治疗、但未接受过免疫治疗的晚期或转移性透明细胞肾细胞癌（ccRCC）成人患者中，Opdivo皮下注射剂与静脉注射剂相比，在PK主要终点上达非劣性。28天平均血药浓度的几何均数比（GMR）为2.10（90% CI：2.00–2.20），稳态谷浓度的GMR为1.77（90% CI：1.63–1.93）。此外，在关键次要终点客观缓解率（ORR）上，Opdivo皮下注射剂组为24%（95% CI：19–30），而静脉注射剂组为18%（95% CI：14–24），显示Opdivo两种剂型在疗效方面具有相似性。超90%患者肿瘤缩小！潜在“best-in-class”小分子3期试验达主要终点德国默克（Merck KGaA）今日公布了MANEUVER临床3期试验第一部分的详细积极结果。该试验评估了由与和誉医药（Abbisko Therapeutics）联合开发的集落刺激因子-1受体（CSF-1R）抑制剂pimicotinib用于治疗腱鞘巨细胞瘤（TGCT）患者的疗效。分析显示，每日一次口服的pimicotinib在试验第25周达到主要终点——由盲法独立评审委员会（BIRC）评估的客观缓解率显著优于安慰剂，分别为54.0%与3.2%（p<0.0001）。研究还在所有与TGCT相关的关键患者报告结局的次要终点上显示出具有统计学意义且临床显著的改善。Pimicotinib起效迅速，在13周时已有41.3%的患者（63人中的26人）达成客观缓解。在主要分析数据截止时，BIRC根据RECIST v1.1标准评估发现，几乎所有pimicotinib组患者（63人中的58人，92.1%）的肿瘤体积出现缩小，其中1人获得完全缓解，33人获得部分缓解。而针对TGCT专门设定的终点指标——肿瘤体积评分（TVS）显示，近三分之二接受pimicotinib治疗患者的肿瘤体积减少至少50%（pimicotinib组61.9% vs安慰剂组3.2%，p<0.0001）。Pimicotinib（ABSK021）是和誉医药研发的一款口服、高选择性与活性、潜在“best-in-class”的CSF-1R小分子抑制剂，用于治疗不可手术的腱鞘巨细胞瘤。参考资料：[1] PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee. Retrieved May 28, 2025 from https://www.gsk.com/en-gb/media/press-releases/pivot-po-phase-iii-study-for-tebipenem-hbr-stopped-early-for-efficacy-following-review-by-independent-data-monitoring-committee/[2] Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications. Retrieved May 28, 2025 from https://investors.bms.com/iframes/press-releases/press-release-details/2025/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-the-Subcutaneous-Formulation-of-Opdivo-nivolumab-Across-Multiple-Solid-Tumor-Indications/default.aspx[3] Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor. Retrieved May 28, 2025 from https://www.businesswire.com/news/home/20250527338086/en/Pimicotinib-Demonstrates-Best-in-Class-Potential-with-Significant-Efficacy-and-Clinically-Meaningful-Improvements-in-Patients-with-Tenosynovial-Giant-Cell-Tumor免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床3期临床结果上市批准免疫疗法

2025-05-28

·医药笔记

Spero股价大涨200%：首个口服碳青霉烯类抗生素三期临床成功

▎Armstrong2025年5月28日，葛兰素史克与Spero Therapeutics宣布Tebipenem HBr治疗复杂尿路感染（cUTIs）的三期临床PIVOT-PO由于疗效提前终止。这一决定是基于IDMC根据1690例患者中期分析数据给出的建议。Tebipenem HBr将成为首款口服碳青霉烯类抗生素。该三期临床达到了相比于静脉注射亚胺培南－西拉司丁钠的非劣效性主要终点。受此消息影响，Spero Therapeutics盘前股价大涨227%，市值达到1.3亿美元。该三期临床原本计划入组2628例患者。2022年9月22日，葛兰素史克引进Tebipenem HBr在除日本和其他亚洲国家以外的全球权益，Spero Therapeutics获得6600万美元的首付款，900万美元股权投资，以及额外的5.5亿美元里程碑付款。总结Tebipenem HBr为Spero Therapeutics的核心管线，为一款口服可利用的碳青霉烯类抗生素前药，在肠细胞快速转化为活性药物分子。Armstrong技术全梳理系列GPRC5D靶点全梳理；CD40靶点全梳理；CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向；Claudin 6靶点全梳理；Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇；CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理；Ambrx技术全梳理；Vir Biotech技术全梳理；Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理；Momenta技术全梳理；NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

临床3期引进/卖出抗体药物偶联物

2025-05-28

·FierceBiotech

GSK\'s $66M bet on Spero\'s rejected UTI antibiotic pays off with a phase 3 win

GSK recently scored a regulatory success against complicated UTIs when the FDA approved Blujepa.\n GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh phase 3 readout.The trial of 1,690 hospitalized patients with complicated urinary tract infections (cUTIs) has been halted early after it looked certain that the candidate, called tebipenem HBr, would hit the study’s primary endpoint of showing its non-inferiority to intravenous treatment with the antibiotic imipenem/cilastatin.Armed with the new phase 3 data, GSK is planning its own push for a potential FDA review this year. If it gets the nod from the regulator, tebipenem HBr would become the first oral carbapenem antibiotic available for U.S. patients with cUTIs, GSK pointed out in a May 28 release.“Complicated UTIs can have a profound impact on patients and carry a high risk of clinical complications, including sepsis and septic shock,” GSK Chief Scientific Officer Tony Wood, Ph.D., said in the release.“Currently, many need hospital-based intravenous treatment due to limited oral options for drug-resistant infections, contributing to over $6 billion per year in U.S. healthcare costs,” Wood added. “These positive results add to our growing anti-infectives portfolio and reinforce the potential of tebipenem HBr as an effective oral alternative taken at home.”GSK recently scored a regulatory success against uncomplicated UTIs when the FDA approved its antibiotic Blujepa, also known as gepotidacin, in March. The Big Pharma saw similar promise in tebipenem HBr back in 2022, despite the FDA having at the time recently rejected Spero’s approval application. The biotech used the $66 million upfront payment it received from GSK as part of the licensing deal to fund the phase 3 trial that read out today.“Achieving the primary endpoint in the PIVOT-PO trial marks a significant milestone for tebipenem HBr,” Spero’s CEO Esther Rajavelu said in this morning’s release. “If approved, we believe tebipenem HBr is well-positioned to change the treatment landscape for patients diagnosed with cUTI, including pyelonephritis.”The late-stage win for tebipenem HBr is a welcome boost for Spero, which has spent the past year navigating layoffs and stripping back its pipeline. This included halting work on the oral antibiotic SPR720 after it failed to beat placebo and showed signs of liver toxicity in a phase 2 trial for non-tuberculous mycobacterial pulmonary disease.The low return on investment means many of the biggest biopharmas have given up working on new antifungals or antibiotics in recent years—although GSK in particular has continued to sign deals and post encouraging clinical results against infections like gonorrhea.

$GSK\'s $66M bet on Spero\'s rejected UTI antibiotic pays off with a phase 3 win$

临床3期临床2期引进/卖出

100 项与替比培南酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09598	替比培南酯	J01DH06	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
中耳炎	日本	Meiji Seika Pharma Co., Ltd.	2009-04-22
肺炎	日本	Meiji Seika Pharma Co., Ltd.	2009-04-22
鼻窦炎	日本	Meiji Seika Pharma Co., Ltd.	2009-04-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复杂的尿路感染	申请上市	美国	Spero Therapeutics, Inc.	2021-10-28
脓尿	临床3期	美国	GSK Plc	2023-12-21
脓尿	临床3期	美国	Spero Therapeutics, Inc.	2023-12-21
脓尿	临床3期	阿根廷	Spero Therapeutics, Inc.	2023-12-21
脓尿	临床3期	阿根廷	GSK Plc	2023-12-21
脓尿	临床3期	波斯尼亚和黑塞哥维那	GSK Plc	2023-12-21
脓尿	临床3期	波斯尼亚和黑塞哥维那	Spero Therapeutics, Inc.	2023-12-21
脓尿	临床3期	巴西	Spero Therapeutics, Inc.	2023-12-21
脓尿	临床3期	巴西	GSK Plc	2023-12-21
脓尿	临床3期	保加利亚	Spero Therapeutics, Inc.	2023-12-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06059846 (PIVOT-PO, NEWS) 人工标引	临床3期	复杂的尿路感染	1,690	tebipenem HBr	觸鬱糧選蓋鬱鏇淵顧積(積鹹鹽觸簾鏇廠簾積觸) = tebipenem HBr achieved non-inferiority compared to IV imipenem cilastatin 夢構選醖鹽積觸醖範艱 (網鏇網膚夢範廠衊艱餘 )	非劣	2025-05-28
				imipenem cilastatin
NCT03788967 (ADAPT-PO, CTgov)	临床3期	急性肾盂肾炎 \| 复杂的尿路感染	1,372	Dummy Infusion+TBPM-PI-HBr (TBPM-PI-HBr 600 mg)	鑰糧鹹築蓋網襯襯夢糧 = 壓願範顧醖廠夢鹽醖選壓餘鬱膚廠窪蓋積願襯 (淵構鬱觸築鏇窪衊廠獵, 構齋遞鏇觸選膚憲遞膚 ~ 繭蓋齋蓋壓廠窪襯醖鹽) 更多	-	2022-07-25
				Dummy tablets+Ertapenem (Ertapenem 1 g)	鑰糧鹹築蓋網襯襯夢糧 = 膚糧鏇廠衊製鏇鏇獵遞壓餘鬱膚廠窪蓋積願襯 (淵構鬱觸築鏇窪衊廠獵, 網糧糧憲蓋築繭鏇艱網 ~ 繭鬱顧襯膚壓壓壓網鹽) 更多
NCT04178577 (Pubmed \| Antimicrob Agents Chemother)	临床1期	肾功能不全	39	Tebipenem Pivoxil Hydrobromide (Cohort 1 (normal renal function))	鹽範築築選築觸衊鹹醖(鹽鹽築觸餘製網憲顧鬱) = 壓築艱窪艱鏇獵艱衊鏇選襯糧鏇壓遞繭憲積蓋 (蓋網憲鏇簾餘醖網糧憲 ) 更多	-	2022-04-14
				Tebipenem Pivoxil Hydrobromide (Cohort 3 (moderate renal impairment))	淵蓋網簾簾窪製簾簾範(淵繭鬱夢構願夢簾選廠) = 獵餘窪鹹鑰鏇製憲膚窪膚鹹鹽鹽積鏇觸齋遞築 (憲網繭膚餘襯淵窪齋淵 )
NCT03788967 (ADAPT-PO, Pubmed \| N Engl J Med)	临床3期	复杂的尿路感染	1,372	Tebipenem pivoxil hydrobromide	糧遞製構蓋網膚艱齋網(遞築憲窪醖鬱壓壓鹽醖) = 窪淵鑰鹽鹽衊廠鑰選鹽簾鏇築製窪獵構簾獵窪 (觸餘淵觸蓋遞窪餘餘衊 ) 更多	积极	2022-04-07
				Intravenous ertapenem	糧遞製構蓋網膚艱齋網(遞築憲窪醖鬱壓壓鹽醖) = 繭壓簾觸願齋糧鏇製廠簾鏇築製窪獵構簾獵窪 (觸餘淵觸蓋遞窪餘餘衊 ) 更多
NCT03788967 (ADAPT-PO, GlobeNewswire) 人工标引	临床3期	泌尿道感染 \| 急性肾盂肾炎	1,372	tebipenem HBr	遞觸憲壓獵獵製衊選鏇(選夢簾窪艱選製夢鹹積) = 築淵憲願構製願廠壓觸夢鹽襯鏇構選積壓範憲 (鹹醖壓廠觸夢繭鹹鑰獵 ) 更多	非劣	2020-09-08
				Ertapenem Sodium	遞觸憲壓獵獵製衊選鏇(選夢簾窪艱選製夢鹹積) = 願觸壓淵壓顧憲蓋餘艱夢鹽襯鏇構選積壓範憲 (鹹醖壓廠觸夢繭鹹鑰獵 ) 更多